Literature DB >> 25297026

Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat.

H B Pandya1, Harihar Har Agravat, J S Patel, N R K Sodagar.   

Abstract

BACKGROUND: Antimicrobial resistance is a growing problem in H. pylori treatment. The study was intended to evaluate the prevalence of resistance amongst 80 H.pylori isolates cultured from biopsy taken during routine endoscopies in 2008-2011.
MATERIALS AND METHODS: 855 gastro duodenal biopsies were collected and cultured on H.pylori selective medium (containing Brucella agar and Columbia agar (Hi media), with Skirrow's supplement (antibiotic supplement) and 7% human blood cells). H.pylori was isolated from 80 specimens. The antimicrobial susceptibility of H.pylori isolates was carried out by the Kirby Bauer technique against metronidazole (5 µg), clarithromycin (15 µg), ciprofloxacin (5 µg), amoxicillin (10 µg), tetracycline (30 µg), erythromycin (15 µg), levofloxacin (5 µg), and furazolidone (50 µg) (Sigma- Aldrich, MO).
RESULTS: 83.8% isolates were resistant to metronidazole, 58.8% were resistant to Clarithromycin 72.5% were resistant to Amoxicillin, 50% to Ciprofloxacin and 53.8% to tetracycline. furazolidone, erythromycin and Levofloxacin showed only 13.8% resistance to H.pylori. Multi drug resistance with metronidazole+clarithromycin+tetracycline was 85%. For all the drugs Antimicrobial resistance rate was found higher in males compare to females. Metronidazole and amoxicillin resistance was found noteworthy in patients with duodenal ulcer (p=0.018), gastritis (P=0.00), and in reflux esophagitis (P=0.00). clarithromycin and tetracycline resistance was suggestively linked with duodenitis (P=0.018), while furazolidone, erythromycin and levofloxacin showed excellent sensitivity in patients with duodenitis (P value--0.018), gastritis (P=0.00) and reflux esophagitis (P=0.00). Resistance with metronidazole (P=0.481), clarithromycin (P=0.261), amoxicillin (P=0.276), tetracycline (P=0.356), ciprofloxacin (P=0.164) was not correlated well with Age-group and Gender of the patients.
CONCLUSION: A very high percentage of patients were infected with metronidazole and clarithromycin resistant strains. The use of antibiotics for other indications seems to be the major risk factor for the development of primary resistance. High incidence should alarm the gastroenterologist while prescribing the eradication regimen.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25297026     DOI: 10.4103/0255-0857.142256

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  9 in total

Review 1.  Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.

Authors:  Reza Ghotaslou; Hamed Ebrahimzadeh Leylabadlo; Yalda Mohammadzadeh Asl
Journal:  World J Methodol       Date:  2015-09-26

2.  Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial.

Authors:  Sanjeev Kumar Jha; Manish K Mishra; Kuldeep Saharawat; Praveen Jha; Shubham Purkayastha; Ravish Ranjan
Journal:  Indian J Gastroenterol       Date:  2019-09-14

3.  Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.

Authors:  Muhammad Miftahussurur; Pradeep Krishna Shrestha; Phawinee Subsomwong; Rabi Prakash Sharma; Yoshio Yamaoka
Journal:  BMC Microbiol       Date:  2016-11-04       Impact factor: 3.605

4.  Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations.

Authors:  Muhammad Miftahussurur; Ari Fahrial Syam; Iswan Abbas Nusi; Dadang Makmun; Langgeng Agung Waskito; Lukman Hakim Zein; Fardah Akil; Willy Brodus Uwan; David Simanjuntak; I Dewa Nyoman Wibawa; Jimmy Bradley Waleleng; Alexander Michael Joseph Saudale; Fauzi Yusuf; Syifa Mustika; Pangestu Adi; Ummi Maimunah; Hasan Maulahela; Yudith Annisa Ayu Rezkitha; Phawinee Subsomwong; Dadik Rahardjo; Rumiko Suzuki; Junko Akada; Yoshio Yamaoka
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

5.  Resistance of Helicobacter pylori to furazolidone and levofloxacin: A viewpoint.

Authors:  Mohammad Zamani; Arash Rahbar; Javad Shokri-Shirvani
Journal:  World J Gastroenterol       Date:  2017-10-07       Impact factor: 5.742

Review 6.  Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.

Authors:  Muhammad Miftahussurur; Yoshio Yamaoka
Journal:  Molecules       Date:  2015-04-08       Impact factor: 4.411

7.  High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in Helicobacter pylori isolated from Karnataka patients.

Authors:  Mamatha Ballal; Eng Guan Chua; Vignesh Shetty; Binit Lamichhane; Chin Yen Tay; Ganesh C Pai; Ramachandra Lingadakai; Girisha Balaraju; Shiran Shetty
Journal:  Gut Pathog       Date:  2019-05-13       Impact factor: 4.181

Review 8.  Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles.

Authors:  Romelia Pop; Alexandru-Flaviu Tăbăran; Andrei Paul Ungur; Andrada Negoescu; Cornel Cătoi
Journal:  Pharmaceutics       Date:  2022-07-14       Impact factor: 6.525

9.  Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology.

Authors:  Shivaram Prasad Singh; Vineet Ahuja; Uday C Ghoshal; Govind Makharia; Usha Dutta; Showkat Ali Zargar; Jayanthi Venkataraman; Amit Kumar Dutta; Asish K Mukhopadhyay; Ayaskanta Singh; Babu Ram Thapa; Kim Vaiphei; Malathi Sathiyasekaran; Manoj K Sahu; Niranjan Rout; Philip Abraham; Prakash Chandra Dalai; Pravin Rathi; Saroj K Sinha; Shobna Bhatia; Susama Patra; Ujjala Ghoshal; Ujjal Poddar; Venigalla Pratap Mouli; Vikram Kate
Journal:  Indian J Gastroenterol       Date:  2021-07-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.